Cancer in Ireland – Raising Survival Rates

Every year, almost 45.000 people in Ireland are diagnosed with cancer, making Ireland the country with the highest cancer incidence in Europe.

The 5 most diagnosed types of cancer in Ireland are:

  1. Skin cancer
  2. Prostate cancer
  3. Breast cancer
  4. Bowel cancer
  5. Lung cancer

1 out of 4 deaths in Ireland can be attributed to cancer, accounting for roughly 30% of all deaths each year.

That makes cancer the dominant cause of death. Therefore, the fight against cancer is of the utmost importance for Ireland’s public health. Experts expect cancer rates in Ireland to rise in the next two to three decades. If conditions remain stable, the number for men could more than double, and the number for women could nearly double. While it is not possible to make an exact prediction decades into the future, these estimates are nonetheless alarming. Similar to other European countries, the most common cancer in men is prostate cancer and breast cancer in women. Bowel, skin, and lung cancer affect both men and women. 

MVision AI advanced breast model with lymph nodes for cancer radiotherapy on the axillary and the heart area

Breast cancer has the highest mortality among female cancer patients in Ireland.

MVision AI male pelvis model & SBRT model for cancer radiotherapy

Colorectal cancer has one of the highest mortality rates in both men and women in the EU.

There is, however, another important number to be considered: the number of cancer survivors. At this point, more than 173.000 people in Ireland are cancer survivors, that means nearly 4% of the population. Today, 6 out of 10 cancer patients in Ireland are alive 5 years after the initial diagnosis, a significant rise compared to only a few decades ago. In its battle against cancer, Ireland launched a nationwide program to improve cancer care on a systemic level. With efforts to reduce the occurrence of common cancers with preventative measures and campaigns for early detection, there is reason to have hope for the number of survivors to increase even more. Advances in care and technology also significantly impact the prognosis and survival rates. 50%-60% of cancer patients in Ireland receive or could benefit from radiotherapy at some point in their treatment. Therefore, providing the best possible care and radiotherapy treatment options must be a priority.

MVision AI strives to support Irish clinicians and patients in their fight against cancer by helping to make cancer radiotherapy faster, more precise, and therefore safer. As an example, MVision’s prostate cancer auto-segmentation model has shown great promise in retrospective studies. AI and deep-learning-based auto-segmentation and contouring can help clinicians to treat more patients in a shorter amount of time, while also improving the quality of treatment. MVision AI provides high-quality models for radiotherapy for all important cancer indications, as recognised by research and studies.

MVision AI male pelvis model with lymph nodes for prostate treatment

Ireland has the highest incidence of prostate cancer within the EU.

With the expected rise in cancer cases, providing more time-efficient treatment options without compromising accuracy and effectiveness is a crucial step towards improving the one number we care about the most: the number of cancer survivors.

Book a demo to explore GBS™ for your clinic

MVision AI is active on LinkedIn, Twitter, Facebook, and Instagram. Follow us on social media and subscribe to our newsletter to stay up-to-date on the latest MVision AI news.

Are you eager to learn more? We welcome you to contact MVision AI:

c/o Terkko Health Hub, Haartmaninkatu 4, 00290 Helsinki, Finland.

Tel: +358 (0) 40 5489 229

Email: info@mvision.ai

For media inquiries:

+358 40 500 7915; pr@mvision.ai

Sources:

Irish Cancer Society. https://www.cancer.ie/cancer-information-and-support/cancer-information/about-cancer/cancer-statistics

Kiljunen et al., 2020. https://www.mdpi.com/2075-4418/10/11/959

National Cancer Register Ireland. https://www.ncri.ie/data/survival-statistics and

https://www.ncri.ie/publications/cancer-trends-and-projections/cancer-incidence-projections-ireland-2020-2045

MVision AI, 2022. https://mvision.ai/gbs-abstracts-degro-2022/

NCCP, 2021. https://www.hse.ie/eng/services/list/5/cancer/profinfo/medonc/nccp-systemic-anti-cancer-therapy-model-of-care.pdf and https://www.hse.ie/eng/services/list/5/cancer/patient/treat/radio/whatrt.html

The Global Cancer Observatory, 2021. https://gco.iarc.fr/today/data/factsheets/populations/372-ireland-fact-sheets.pdf

Our Newsletter

Subscribe to get information, latest news and other interesting offers about MVision AI

Related Posts

24.10.2024

MVision AI Secures FDA 510(k) Clearance for Contour+ Advanced CT and MR Models

Helsinki, October 2024 – MVision AI, a leading innovator in AI-powered solutions for radiotherapy, is thrilled to announce that its auto-contouring solution Contour+ has received FDA 510(k) clearance for three new models: Bones CT, Brain MR, and Male Pelvis MR T2, and five updated models: Brain CT, Abdomen & Lung…

Press Releases

22.10.2024

Saving Time to Improve Workflow and Patient Comfort: A New AI-Based Solution for Gynaecological Brachytherapy

Navigating Discomfort Radiation therapy is a non-invasive and non-painful cancer treatment. However, some patients might experience mild discomfort during treatment sessions, determined by a variety of factors. Physical discomfort due to positioning and immobilisation represent one of the most common causes [1]. Despite the medical team’s efforts, keeping the same…

Articles

11.10.2024

Baylor College of Medicine and MVision AI Collaborate to Drive AI-Powered Innovations in Radiation Therapy

Helsinki, Finland, October 11, 2024 – Baylor College of Medicine and MVision AI have entered into a strategic research and development agreement to drive innovation in radiation therapy through AI technology. This collaboration aims to accelerate the clinical adoption of AI-powered solutions, enhancing the efficiency and effectiveness of cancer treatment.…

Press Releases